Emiliem, Inc. Press Release - August 4, 2008

Emiliem and NIH Sign CRADA for Clinical Development of Novel mTOR Inhibitors

SAN FRANCISCO-August 4, 2008 Emiliem, Inc. a privately-held biopharmaceutical company focused on discovering and developing novel molecular targeted therapeutics announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for the clinical development of LY303511 (LY3) and analogs for use in proliferative and inflammatory disorders. LY3, now called EM101, is an mTOR pathway inhibitor with a novel mechanism of action identified by Dr. Joel Moss, Deputy Chief of NHLBI’s Translational Medicine Branch, and colleagues at NHLBI. The project will set the stage for clinical trials starting in early 2009 in oncology and non-oncology indications, alone and in combination with other therapeutics. Emiliem acquired the world-wide rights to develop and commercialize this series of compounds in an exclusive licensing agreement with the NIH. Dr. Moss is the principal investigator on the CRADA.

Dale E. Johnson, PharmD, PhD, President and CEO of Emiliem, Inc. and Principal Investigator for Emiliem on the CRADA, stated, “We view the formation of this CRADA utilizing the strong science base at NIH as the ideal way to uncover novel approaches to develop compounds that inhibit the mTOR and related pathways. We expect to jointly establish methodology that will expedite the movement of these compounds to clinical proof-of-concept in multiple indications.”

About the mTOR pathway
Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. Studies have linked mTOR to several human diseases including cancer, inflammation, diabetes, obesity, cardiovascular diseases and neurological disorders. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.

Safe Harbor Statement
This announcement is intended to provide information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in the company. Forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward- looking statements that involve risks and uncertainties, including: dependence on third parties for development, regulatory approval, and commercialization of products; risks developing drug product candidates; and risks and uncertainties inherent within the industry. Actual results may differ materially from those described.

Contact
Dale E. Johnson
510 316 1197
dale@emiliem.com
www.emiliem.com



	HOME \| ABOUT \| CORPORATE \| BUSINESS MODEL\| PIPELINE \| PRESS \| NEWS \| CONTACT

	Emiliem, Inc. Press Release - August 4, 2008 Emiliem and NIH Sign CRADA for Clinical Development of Novel mTOR Inhibitors SAN FRANCISCO-August 4, 2008 Emiliem, Inc. a privately-held biopharmaceutical company focused on discovering and developing novel molecular targeted therapeutics announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Heart Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for the clinical development of LY303511 (LY3) and analogs for use in proliferative and inflammatory disorders. LY3, now called EM101, is an mTOR pathway inhibitor with a novel mechanism of action identified by Dr. Joel Moss, Deputy Chief of NHLBI’s Translational Medicine Branch, and colleagues at NHLBI. The project will set the stage for clinical trials starting in early 2009 in oncology and non-oncology indications, alone and in combination with other therapeutics. Emiliem acquired the world-wide rights to develop and commercialize this series of compounds in an exclusive licensing agreement with the NIH. Dr. Moss is the principal investigator on the CRADA. Dale E. Johnson, PharmD, PhD, President and CEO of Emiliem, Inc. and Principal Investigator for Emiliem on the CRADA, stated, “We view the formation of this CRADA utilizing the strong science base at NIH as the ideal way to uncover novel approaches to develop compounds that inhibit the mTOR and related pathways. We expect to jointly establish methodology that will expedite the movement of these compounds to clinical proof-of-concept in multiple indications.” About the mTOR pathway Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. Studies have linked mTOR to several human diseases including cancer, inflammation, diabetes, obesity, cardiovascular diseases and neurological disorders. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway. Safe Harbor Statement This announcement is intended to provide information regarding initiatives of Emiliem, Inc. It is not intended as a general advertisement nor an offer to sell or a solicitation of an offer to buy any securities or an interest in the company. Forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Except for historical information, matters described are forward- looking statements that involve risks and uncertainties, including: dependence on third parties for development, regulatory approval, and commercialization of products; risks developing drug product candidates; and risks and uncertainties inherent within the industry. Actual results may differ materially from those described. Contact Dale E. Johnson 510 316 1197 dale@emiliem.com www.emiliem.com